Kornimate/medical-research-clean huggingface dataset:
il-6: a marker for aml chemo sensitivity

Conditions: AML, Adult

Summary: acute myeloid leukemia (aml) is a clonal malignancy that arises from the primitive hematopoietic cells within the hematopoietic system. according to seer cancer statistics, the 5-year survival rate for aml patients stands at a concerning 30%. despite therapeutic advancements, the development of chemotherapy resistance and the risk of disease relapse pose significant barriers to curative outcomes. evidence has linked elevated interleukin-6 (il-6) levels in plasma and bone marrow to a poorer prognosis in aml, with il-6 potentially fostering chemotherapy resistance through the enhancement of fatty acid uptake and the induction of stromal-like morphological changes in aml cells. however, the role of il-6 as a potential biomarker for monitoring chemotherapy sensitivity in aml has not been fully elucidated. this study seeks to investigate the correlation between il-6 levels in bone marrow supernatant and the sensitivity to chemotherapy, offering a clinical perspective that could pave the way for improved prognostic markers and personalized treatment strategies.

in this prospective study, we will collect bone marrow supernatant samples from patients diagnosed with acute myeloid leukemia (aml) to evaluate the levels of interleukin-6 (il-6). our aim is to explore whether elevated il-6 levels can serve as a predictive biomarker for poor treatment outcomes following standard chemotherapy regimens. the findings may help in stratifying patient risk and personalizing therapeutic approaches in aml treatment.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis aligns with the "chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not apl) (2023)"; 2. all patients are experiencing their first onset of the disease and have not received any related chemotherapy prior to the study; 3. patients participate in the study accompanied by family members and sign informed consent documents. exclusion criteria: 1. patients with concurrent malignancies requiring treatment; 2. presence of infectious diseases, including sars, viral hepatitis, or hiv/aids; 3. major surgery performed within the last 21 days; 4. performance status (ps) score \>3; 5. severe liver or kidney dysfunction or serious infection; 6. severe psychiatric conditions that impair understanding of the study protocol or voluntary withdrawal.

Keywords: aml il-6 chemotherapy sensitivity
an open-trial of web-prolonged exposure (web-pe) among active-duty military

Conditions: Posttraumatic Stress Disorder; Combat Disorders

Summary: it is urgent to make evidence-based treatments (ebts) for military personnel readily accessible in order to meet the growing demand for effective and efficient treatment for posttraumatic stress disorder (ptsd) in a timely manner. effective ebts for ptsd are available, but barriers to accessing care can deter military personnel from receiving treatment. web-treatments represent an innovative way to overcome these barriers. the efficacy of previously developed web-treatments for ptsd appear promising, however, they are not based on treatment protocols with strong empirical support for their efficacy. no study to date has examined web-treatment of ptsd using a well-established treatment program. the purpose of this open trial is to examine the efficacy of 10 sessions of a web-version of prolonged exposure (pe), "web-pe," delivered over 8-weeks in 40 active-duty military personnel and veterans with ptsd who deployed post 9-11. up to 60 individuals will be consented to obtain data from 40 for analysis. participants will be assessed at pre-treatment and 1- and 3-months after treatment completion.


Eligibility criteria:
inclusion criteria: * active-duty military personnel and veterans who have deployed post 9/11 * seeking treatment for ptsd * significant ptsd symptoms as determined by a pcl-5 score greater than or equal to 31 * has experienced a criterion a event that is a specific combat-related event or high magnitude operational experience that occurred during a period of recent military deployment * able to speak and read english and access to an internet-connected computer * indication that the participant plans to be able to participant in the study for the next three months following the first assessment exclusion criteria: * diagnosis of bipolar disorder or psychotic disorder, as determined by participant self-report) * current substance dependence, as determined by participant self-report) * diagnosis of a moderate or severe traumatic brain injury, as determined by participant self-report) * current suicidal ideation severe enough to warrant immediate attention, as determined by participant self-report) * currently engaged in evidence-based treatment for ptsd (e.g. prolonged exposure therapy or cognitive processing therapy), as determined by participant self-report.

Keywords: combat psychological treatment military psychotherapy trauma posttraumatic stress posttraumatic stress disorder
efficacy and safety of metoprolol tartrate tablets combined with chinese traditional medicine on premature ventricular complex.

Conditions: Premature Ventricular Contraction

Summary: objective: investigators investigated the effects of metoprolol tartrate plus tongmai yangxin pill on premature ventricular complexes and cardiac function in patients with premature ventricular complex. methods: in total, 584 participants with premature ventricular complex will be randomly assigned (at a 1:1 ratio) into two groups: study group (metoprolol tartrate \[25 mg twice per day, orally\] plus tongmai yangxin pill \[40 pills twice per day, orally\]) and control group (metoprolol tartrate \[25 mg twice per day, orally\] plus placebo \[40 simulated pills twice per day, orally\]). the total treatment period is 8 weeks. efficacy endpoints and safety assessment: primary efficacy endpoints are as follows: change in 24-h number of pvcs after treatment and effective rate of 24-h number of pvcs after treatment. secondary efficacy endpoints are as follows: change in new york heart association classification; total effective rate of comprehensive effect; change in high-sensitivity c-reactive protein level; and change in echocardiography parameters (i.e., left ventricular ejection fraction, left ventricular end diastolic dimension, e/a, cardiac index, cardiac output, and stroke volume).


Eligibility criteria:
inclusion criteria: * lown pvc grade, ii-iva; * in patients with coronary heart disease and comorbid pvc or non-organic heart disease, the pvc frequency was 3000-30000 times/24 h; * new york heart association grade, i or ii; * ejection fraction, ≥45%; * written informed consent to participate in the trial. exclusion criteria: * presence of bradyarrhythmia (\<50 beats/min), including sinus syndrome and atrioventricular block (second or third degree atrioventricular block); * presence of persistent ventricular tachycardia, non-persistent ventricular tachycardia, and/or persistent atrial fibrillation; * presence of severe pvc requiring treatment with other antiarrhythmic drugs; -presence of drug-induced, electrolyte-induced, or acid-base-induced arrhythmia; * presence of uncontrolled or severe hypertension (e.g., grade ≥3 hypertension); * presence of uncontrolled diabetes; presence of alanine aminotransferase or aspartate aminotransferase level ≥1.5-fold above the upper limit of normal, urea nitrogen level ≥1.2-fold above the upper limit of normal, and/or blood creatinine above the upper limit of normal; * presence of severe respiratory dysfunction or asthma; * presence of primary hematopoietic diseases, other systemic diseases (e.g., hyperthyroidism), poor peripheral circulation perfusion, severe peripheral vascular diseases, and/or pvc with unknown etiology; * presence of allergic constitution, mental disorder, alcoholism, and/or smoking habit; * pregnancy or lactation; * ongoing β-blocker treatment or contraindications to β-blocker treatment; -participation in other clinical trials within the prior 3 months; * and other reasons for lack of suitability to participate in this study, as determined by the investigators.
first line chemotherapy treatment of advanced non-small cell lung cancer (nsclc)

Conditions: Non-Small Cell Lung Cancer

Summary: the purposes of this study are to determine: the safety of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin, or docetaxel with carboplatin and any side effects that might be associated with the combination of these drugs. whether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and carboplatin can help participants with non-small cell lung cancer (nsclc) live longer, compared with the combination of docetaxel and carboplatin. whether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and carboplatin can make your tumor smaller or disappear, and for how long, compared with the combination of docetaxel and carboplatin. the effects of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin or docetaxel with carboplatin have on your disease related symptoms. the relation of smoking history and hormone replacement therapy (for women only) may have to your lung cancer treatment results. the effects of certain genes and proteins in samples of your blood and tumor tissue in order to learn more about nsclc and how enzastaurin works in the body.


Eligibility criteria:
inclusion criteria: * you must have been diagnosed with nsclc. * you must be able to visit the doctor's office weekly during the active treatment period and as needed during the study follow-up period. * you must be willing and able to swallow capsules. * your entry labs and medical tests must meet study requirements. * you must be willing to have blood samples drawn and tissue samples obtained for gene and protein testing. exclusion criteria: * you have received radiation within 2 weeks of study enrollment. * you have previously received any anti-cancer drug therapy for nsclc. * you have an active infection or other serious condition. * you take aspirin or aspirin-like medication regularly and are not able to stop taking them for a few days during each cycle of chemotherapy. * you have recently lost a significant amount of weight.
protocol for primary fractionated stereotactic body radiation therapy for stage t1 - t3n0 non small cell lung carcinoma.

Conditions: Non Small Cell Lung Carcinoma

Summary: the study population will exist of patients with a histological diagnosis of nsclc, stage t1, t2 or t3no who are not fit for or who refuse surgery. a prospective data analysis will be performed on tumor response, potential acute and late toxicity and survival. a radiotherapy dose of 4x15gy or 3x 20gy will be given over 2 weeks with dynamic 3d-conformal arc therapy (novalis tm)


Eligibility criteria:
inclusion criteria: 1. stage t1,t2,t3n0m0 nsclc, histological confirmation either by biopsy or cytology 2. maximal tumor diameter of 6 cm 3. only t3 lesions based upon thoracic wall involvement 4. informed consent is required 5. life expectancy of at least 6 months 6. age \> 18 y. 7. karnofsky score ≥ 70 or ecog score ≤ 1 8. inoperable patients or patients refusing surgery 9. patients with measurable lesion (according to recist criteria) exclusion criteria: 1. diagnosis of small cell lung cancer 2. lymph node involvement 3. prior radiotherapy or chemotherapy for lung cancer 4. pregnant or lactating women 5. known allergy for ct contrast 6. no fdg-pet 7. mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study. 8. patient unlikely to comply with protocol, i.e., uncooperative attitude, inability to return for follow-up visits, extreme degradation of lung function tests and patients not likely to complete the study.

Keywords: nsclc novalis stereotactic sbrt t1, t2 or t3no nsclc
different therapeutical modalities associated to hamstring flexibility training

Conditions: Range of Motion, Articular

Summary: the purpose of this study is to compare the acute effect of the use of different thermal modalities associated to the training of passive flexibility of the hamstring muscles in the amplitude of motion of the knee extension.

context: in the literature there is a disagreement of results and protocols regarding the use of thermal modalities associated with the training of flexibility of the hamstring muscles. most studies on the subject, used the heat and cryotherapy prior to stretching these. therefore, the investigators aimed to conduct an experimental study using the therapeutics term concomitant arrangements to passive static stretching these muscles. methods: clinical trial randomized crossover, which will a sample of 42 subjects (healthy young men, aged 20 to 30 years). were divided into 3 groups (group 1 passive static stretching hamstrings, group 2 heat + passive static stretching hamstrings and group 3 cryotherapy + static stretching hamstrings passive) with 14 subjects each. where the participants will control themselves, since all carry out the three interventions, only at different times. each action will be performed every 7 days. individuals will be subjected to active test of the range of motion of knee extension (goniometer) and hamstring muscle strength (dynamometer).

Eligibility criteria:
inclusion criteria: * healthy men with knee extension range less than or equal to 160 degrees. exclusion criteria: * have exercised in the last 48 hours before the intervention session; * previous neurological, muscular or articular disease that influences the performance of the training; * anterior lower limb surgery; * presence of painful symptoms or edema in the lower limbs; * hypersensitivity to ice or heat; * raynaud's syndrome; * loss of local thermal sensitivity; * have metallic implants; * use of cardiac pacemaker; * presence of malignant tumor; * arterial diseases; * deep venous thrombosis or phlebitis; * fever and inflammatory processes; * bleeding processes; * osteomyelitis; * epilepsy; * pulmonary and bone tuberculosis; * kidney or urinary tract infection; * cryoglobulinemia;

Keywords: pliability cryotherapy hot temperature hyperthermia, induced randomized controlled trial hamstring muscles muscle stretching exercises
frailty of elderly with valvular heart disease and the short term adverse events

Conditions: Frailty; Elderly; Valvular Heart Disease

Summary: despite the rapid development of medical and nursing technology, the prognosis of valvular heart disease has been greatly improved. however, compared with young patients, the mortality and adverse event rate of elderly patients with valvular heart disease are still high, surgical complications are more frequent and hospitalization time is longer. the complexity of valvular heart disease and the poor prognosis in the elderly forces us to continue to look for other potential prognostic factors. in addition to the adverse outcomes caused by disease factors, elderly patients with valvular heart disease also have the gradual decline of physiological and psychological reserve function caused by age factors. these adverse outcomes include osteopenia, disability, prolonged hospitalization and even death are all closely related to frailty. frailty is 'a biologic syndrome of decreased reserve and resistance to stressors, resulting from cumulative declines across multiple physiologic systems, and causing vulnerability to adverse outcomes. the essence of frailty is the decline of individual resistance, which eventually leads to the increase of individual brittleness and susceptibility to adverse health outcomes. at present, the research in the field of elderly vulnerable groups of cardiovascular disease in china started late, mostly focusing on the study of pathological mechanism, the introduction of evaluation tools, conceptual analysis and so on. almost all of the existing studies are about the debilitation status of elderly patients with heart valve disease, and most of them mainly try to find the influencing factors of debilitation from the aspects of patients' physical diseases, ignoring the impact of factors such as the mental health status of the elderly on debilitation, there are few reports of short-term adverse events in elderly patients with valvular heart disease. this study will analyze the influencing factors of the weakness of elderly patients with valvular diseases from the multi-dimensional aspects of demographic data, physical diseases, psychology and society, and track the short-term prognosis of patients with death, fall and unconventional rehospitalization, so as to provide a research basis for relevant research in the future.


Eligibility criteria:
inclusion criteria: * age ≥ 65 years; * willing to continue to participate in this study; * diagnosed as valvular heart disease exclusion criteria: * suffering from other irreversible serious diseases; * with severe mental disorders; * cannot accept frailty assessment due to treatment needs and other factors.
axial length variability

Conditions: Cataract Senile

Summary: the accuracy of iol calculation relies on the one hand on axial length measurements and on the other hand on corneal and lens thickness measurements. al difference in pre and postoperative measurements may be caused by changes of lens parameters. aim of this study is to evaluate the magnitude of changes in pre and postoperative measurements of al.

this is a prospective observational, controlled and unmasked study that would include patients which undergo cataract presurgical examination, after patient signed written informed consent. for each patient only one eye will be included. in total 50 eyes of 50 patients will be include. due to missing previous data, the sample size is an approximation. prior to surgery, slit lamp examination and cataract grading (locs) is performed. routine biometry is performed using the iol master 700 (carl zeiss meditec ag, jena, germany) and heidelberg anterion (heidelberg engineering, germany) for al and lens measurement. additionally, evaluation of tilt and decentration will be performed using purkinje meter device. follow-up examination will be performed three months after surgery and will contain: al and lens measurement using the two ss-oct biometery devices, lens evaluation (tilt and decentration of the iol) using the purkinje meter. refractive outcome will be evaluated by determining best-corrected visual acuity and subjective refraction. in women of childbearing age, a pregnancy test will be performed before inclusion into the study. main outcome variable: • extend of al difference between pre- and postoperative measurements in both devices additional outcome variables: * agreement between the two ss-oct devices in al measurement * evaluation of lens parameter in al differences between pre- and postoperative measurements * limit of agreement in lens tilt and decentration using two ss-oct devices and purkinje meter

Eligibility criteria:
inclusion criteria: * uneventful cataract surgery * age 21 and older * axial length 24.00 mm and bigger * ct asphina 409 m lens implanted exclusion criteria: * intra- or postoperative complication * relevant other ophthalmic diseases that are likely to influence the measurement outcome (as: with severe corneal pathology, severe macular degeneration, severe diabetic retinopathy, dens cataract, pex syndrome, previous ocular surgery or trauma) * pregnancy
stabil study: national study with mircera for maintenance of hemoglobin level in dialysis patients

Conditions: Anemia

Summary: this single arm study will assess the efficacy, safety and tolerability of once-monthly administration of intravenous mircera for the maintenance of hemoglobin levels in dialysis participants with chronic renal anemia. participants will receive monthly intravenous injections of mircera, at a starting dose of 120, 200 or 360 micrograms, according to the dose of epoetin administered in the week preceding first study drug administration. the anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * chronic renal anemia; * continuous stable intravenous maintenance epoetin therapy during previous month; * regular long-term hemodialysis therapy with the same mode of dialysis for previous 3 months. exclusion criteria: * transfusion of red blood cells during previous 2 months; * poorly controlled hypertension, that is, sitting blood pressure exceeding 170/100 millimeter of mercury (mmhg) despite medication; * significant acute or chronic bleeding.
providing evidence-based approaches for caregiver stress study

Conditions: Caregiving Stress; Dementia

Summary: the purpose of this preliminary study is to examine the effects of adult day service use on subjective and physiological measures of stress in 50 black informal caregivers for individuals with dementia (iwd). the pi of the proposed study has substantial training in primary data collection and complex-survey secondary data analysis, she also has the fundamental knowledge to investigate how sociocultural and behavioral factors can influence psychosocial stress. the proposed study will enroll participants from adult day service (ads) nationally, to examine the effects of adult day service use on subjective and physiological measures of stress in 50 black informal caregivers. the proposed study extends the current science on the use of ads on subjective and physiological stress by 1) examining differential impacts of ads specifically on subjective measures of stress for black caregivers, 2) evaluating the impact of ads use on physiological measures of stress among black caregivers; and 3) examining the relationship between subjective indicators and physiological processes for black caregivers.


Eligibility criteria:
inclusion criteria: * 18 years or older (male or female) * self-identify as black and/or african american, * lives with a family member with a physician diagnosis of alzheimer's disease or related dementia * primary responsibility for care of the family member who has been diagnosed with alzheimer's disease or related dementia * utilize adult day services at least two times a week for family member with alzheimer's disease or related dementia exclusion criteria: * either caregiver of client is in active treatment for a terminal illness or are in hospice.
provocative tests for hfpef

Conditions: Heart Failure With Preserved Ejection Fraction

Summary: diagnosing heart failure with preserved ejection fraction (hfpef) in patients complaining exertional breathlessness can be challenging: diagnostic algorithms and scores have low sensitivity, and ageing-associated comorbidities can complicate the interpretation of symptoms. thus, exercise right heart catheterization (rhc) or invasive cardiopulmonary exercise test (icpet) have been advocated as gold-standard methods for hfpef diagnosis. however, exercise rhc and icpet are still not widely standardized methods, with results mainly coming from us cohorts (that may differ from italian cohorts), and other provocative tests (e.g. non-invasive cpet, passive leg raising) may offer complementary diagnostic information.


Eligibility criteria:
inclusion criteria: * dyspnea exclusion criteria: * known hfpef